Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Withdrawn 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 12Myelodysplastic Syndromes 4Neoplasm Metastasis 3Melanoma 3Leukemia, Myelomonocytic, Chronic 3Breast Neoplasms 3Advanced Solid Tumor 3Recurrence 2Ovarian Neoplasms 2Lymphoma, B-Cell 2Leukemia, Monocytic, Acute 2Fallopian Tube Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Papillomavirus Infections 1Non-Squamous Non-small Cell Lung Cancer 1Neoplasms 1Nasopharyngeal Carcinoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Microsatellite Instability 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myelomonocytic, Acute 1Leukemia, Basophilic, Acute 1Leukemia 1

Interventions

Cyclophosphamide 16fludarabine 9fludarabine phosphate 8Rituximab 5Whole-Body Irradiation 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Melphalan 4Cytarabine 4Busulfan 4Azacitidine 4AP 1903 reagent 4venetoclax 3ruxolitinib 3ibrutinib 3Tacrolimus 3Prednisone 3Methotrexate 3Mesna 3Etoposide 3pegaspargase 2obinutuzumab 2ivosidenib 2Vincristine 2Patient Reported Outcome Measures 2Observation 2Mercaptopurine 2Leucovorin 2Doxorubicin 2Dexamethasone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia × Injections × Clear all
NCT04874480 2026-01-09

Tegavivint for the Treatment of Relapsed or Refractory Leukemia

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
9 enrolled
Other hematologic neoplasm

Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡